About TFIIA-alpha and beta-like factor
TFIIA-alpha and beta-like factor (GTF2A1L) is a protein
from Homo sapiens identified by UniProt accession
Q9UNN4, 478 residues long.
MolForge cross-references it against 0 known binders and
32 disease associations.
Target properties
| Protein name | TFIIA-alpha and beta-like factor |
| UniProt accession | Q9UNN4 |
| Gene | GTF2A1L |
| Organism | Homo sapiens |
| Length | 478 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (32)
Diseases linked to this target (Open Targets).
- Leydig cell hypoplasia, type 1 · score 0.56
- peripheral precocious puberty · score 0.54
- Leydig cell hypoplasia · score 0.47
- pseudohermaphroditism · score 0.33
- testosterone measurement · score 0.31
- body mass index · score 0.31
- age at menopause · score 0.26
- neurodegenerative disease · score 0.23
- mean corpuscular hemoglobin · score 0.20
- triglyceride measurement · score 0.20
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9UNN4-F1 | alphafold | PREDICTED | 53.00 | — |
Amino-acid sequence (478 residues)
MACLNPVPKL YRSVIEDVIE GVRNLFAEEG IEEQVLKDLK QLWETKVLQS KATEDFFRNS IQSPLFTLQL PHSLHQTLQS STASLVIPAG RTLPSFTTAE LGTSNSSANF TFPGYPIHVP AGVTLQTVSG HLYKVNVPIM VTETSGRAGI LQHPIQQVFQ QLGQPSVIQT SVPQLNPWSL QATTEKSQRI ETVLQQPAIL PSGPVDRKHL ENATSDILVS PGNEHKIVPE ALLCHQESSH YISLPGVVFS PQVSQTNSNV ESVLSGSASM AQNLHDESLS TSPHGALHQH VTDIQLHILK NRMYGCDSVK QPRNIEEPSN IPVSEKDSNS QVDLSIRVTD DDIGEIIQVD GSGDTSSNEE IGSTRDADEN EFLGNIDGGD LKVPEEEADS ISNEDSATNS SDNEDPQVNI VEEDPLNSGD DVSEQDVPDL FDTDNVIVCQ YDKIHRSKNK WKFYLKDGVM CFGGRDYVFA KAIGDAEW
Explore TFIIA-alpha and beta-like factor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets